Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2012, Article ID 810428, 5 pages
http://dx.doi.org/10.1155/2012/810428
Case Report

Bilateral De Quervain Syndrome after Aromatase Inhibitor Administration: A Case Report and Review of the Literature

1Department of Medical Oncology, BOC Oncology Centre, Nicosia, 2006 Strovolos, Cyprus
2First Department of Medical Oncology, Saint Savvas Anticancer Hospital, Athens, Greece
3First Orthopedic Surgery Department, Evangelismos Hospital, Athens, Greece
4Department of Radiation Oncology, BOC Oncology Centre, Nicosia, 2006 Strovolos, Cyprus
5Medical Oncology Unit, Hipokrateion Hospital, Athens, Greece

Received 18 November 2011; Accepted 1 February 2012

Academic Editor: Faustino R. Pérez-López

Copyright © 2012 Konstantinos Papadimitriou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. E. Goss, J. N. Ingle, S. Martino et al., “A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,” New England Journal of Medicine, vol. 349, no. 19, pp. 1793–1802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Baum, A. U. Buzdar, J. Cuzick et al., “Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial,” The Lancet, vol. 359, no. 9324, pp. 2131–2139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Coombes, L. Kilburn, C. Snowdon et al., “Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial,” The Lancet, vol. 369, no. 9561, pp. 559–570, 2007. View at Publisher · View at Google Scholar
  4. A. Buzdar, A. Howell, J. Cuzick et al., “Arimidex, tamoxifen, alone or in combination trialists' group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial,” Lancet Oncology, vol. 7, no. 8, pp. 633–643, 2006. View at Google Scholar
  5. H. A. Martens, C. P. Schroder, P. J. M. van der Eerden, P. H. B. Willemse, and M. D. Posthumus, “Severe disabling tendinopathy caused by anastrazole,” Rheumatology, vol. 46, no. 10, pp. 1619–1621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Morales, S. Pans, K. Verschueren et al., “Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3147–3152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Nishihori, J. Choi, M. P. DiGiovanna et al., “Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer,” Clinical Breast Cancer, vol. 8, no. 4, pp. 362–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. E. Coleman, W. W. Bolten, M. Lansdown et al., “Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations,” Cancer Treatment Reviews, vol. 34, no. 3, pp. 275–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Dizdar, L. Ozcakar, F. U. Malas et al., “Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia,” Journal of Clinical Oncology, vol. 27, no. 30, pp. 4955–4960, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Sestak, F. Sapunar, and J. Cuzick, “Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial,” Journal of Clinical Oncology, vol. 27, no. 30, pp. 4961–4965, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Morales, S. Pans, R. Paridaens et al., “Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging,” Breast Cancer Research and Treatment, vol. 104, no. 1, pp. 87–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Briot, M. Tubiana-Hulin, L. Bastit, I. Kloos, and C. Roux, “Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study,” Breast Cancer Research and Treatment, vol. 120, no. 1, pp. 127–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Pandya and G. J. Morris, “Toxicity of Aromatase Inhibitors,” Seminars in Oncology, vol. 33, no. 6, pp. 688–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. T. Felson and S. R. Cummings, “Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation,” Arthritis and Rheumatism, vol. 52, no. 9, pp. 2594–2598, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Brufsky, “Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update,” Seminars in Oncology, vol. 33, no. 7, pp. 13–17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Coombes, R. Paridaens, C. Jassem et al., “First mature analysis of the intergroup exemestane study,” Journal of Clinical Oncology, ASCO Annual Procceedings, vol. 24, supplement 18, 2006, Abstr LBA527. View at Google Scholar
  17. O. S. Din, D. Dodwell, R. J. Wakefield, and R. E. Coleman, “Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?” Breast Cancer Research and Treatment, vol. 120, no. 3, pp. 525–538, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Baillet, C. Gaujoux-Viala, G. Mouterde et al., “Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis,” Rheumatology, vol. 50, no. 6, pp. 1137–1147, 2011. View at Google Scholar
  19. D. Hayashi, F. W. Roemer, A. Katur et al., “Imaging of synovitis in osteoarthritis: current status and outlook,” Seminars in Arthritis and Rheumatism, vol. 41, no. 2, pp. 116–130, 2011. View at Publisher · View at Google Scholar
  20. N. L. Henry, J. T. Giles, D. Ang et al., “Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors,” Breast Cancer Research and Treatment, vol. 111, no. 2, pp. 365–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. A. Flores, P. Shughrue, S. L. Petersen, and S. S. Mokha, “Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat,” Neuroscience, vol. 118, no. 3, pp. 769–778, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. C. B. Eckersell, P. Popper, and P. E. Micevych, “Estrogen-induced alteration of μ-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala,” Journal of Neuroscience, vol. 18, no. 10, pp. 3967–3976, 1998. View at Google Scholar · View at Scopus
  23. M. Dawson-Basoa and A. R. Gintzler, “Involvement of spinal cord δ opiate receptors in the antinociception of gestation and its hormonal simulation,” Brain Research, vol. 757, no. 1, pp. 37–42, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Morel, H. Marotte, and P. Miossec, “Will steroidal aromatase inhibitors induce rheumatoid arthritis?” Annals of the Rheumatic Diseases, vol. 66, no. 4, pp. 557–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. L. Salem, “Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production,” Current Drug Targets, vol. 3, no. 1, pp. 97–104, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Huang, P. D. Ross, E. Lydick, and R. D. Wasnich, “Factors associated with joint pain among postmenopausal women,” International Journal of Obesity, vol. 21, no. 5, pp. 349–354, 1997. View at Google Scholar
  27. A. Toesca, A. Pagnotta, A. Zumbo, and R. Sadun, “Estrogen and progesterone receptors in carpal tunnel syndrome,” Cell Biology International, vol. 32, no. 1, pp. 75–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. G. A. Greendale, B. A. Reboussin, P. Hogan et al., “Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial,” Obstetrics and Gynecology, vol. 92, no. 6, pp. 982–988, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. M. C. Nevitt, D. T. Felson, E. N. Williams, and D. Grady, “The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: the heart and estrogen/progestin replacement study, a randomized, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 44, no. 4, pp. 811–818, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Evrard, M. Baillien, A. Foidart, P. Absil, N. Harada, and J. Balthazart, “Localization and controls of aromatase in the quail spinal cord,” Journal of Comparative Neurology, vol. 423, no. 4, pp. 552–564, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Riley, M. E. Robinson, E. A. Wise, and D. Price, “A meta-analytic review of pain perception across the menstrual cycle,” Pain, vol. 81, no. 3, pp. 225–235, 1999. View at Publisher · View at Google Scholar · View at Scopus